GB0001448D0 - Organic compounds - Google Patents

Organic compounds

Info

Publication number
GB0001448D0
GB0001448D0 GBGB0001448.0A GB0001448A GB0001448D0 GB 0001448 D0 GB0001448 D0 GB 0001448D0 GB 0001448 A GB0001448 A GB 0001448A GB 0001448 D0 GB0001448 D0 GB 0001448D0
Authority
GB
United Kingdom
Prior art keywords
organic compounds
compounds
organic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0001448.0A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0001448(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Priority to GBGB0001448.0A priority Critical patent/GB0001448D0/en
Publication of GB0001448D0 publication Critical patent/GB0001448D0/en
Priority to MYPI20010226A priority patent/MY155269A/en
Priority to CO01003434A priority patent/CO5261584A1/es
Priority to RU2002121649/13A priority patent/RU2264413C2/ru
Priority to DK01905671.2T priority patent/DK1248804T4/da
Priority to CZ20022531A priority patent/CZ302738B6/cs
Priority to ARP010100247A priority patent/AR027253A1/es
Priority to SI200130698T priority patent/SI1248804T2/sl
Priority to AT01905671T priority patent/ATE346868T1/de
Priority to US10/181,324 priority patent/US20030124617A1/en
Priority to MXPA02007091A priority patent/MXPA02007091A/es
Priority to ES01905671T priority patent/ES2274865T5/es
Priority to PL356297A priority patent/PL207642B1/pl
Priority to HK03102022.5A priority patent/HK1050013A1/zh
Priority to KR1020027009374A priority patent/KR100697126B1/ko
Priority to TR2002/01780T priority patent/TR200201780T2/xx
Priority to DE60124863T priority patent/DE60124863T3/de
Priority to HU0204156A priority patent/HUP0204156A3/hu
Priority to NZ519936A priority patent/NZ519936A/en
Priority to PCT/EP2001/000591 priority patent/WO2001053353A2/en
Priority to SK1035-2002A priority patent/SK288054B6/sk
Priority to PE2001000065A priority patent/PE20011219A1/es
Priority to CN018039529A priority patent/CN1395581B/zh
Priority to EP01905671A priority patent/EP1248804B2/en
Priority to AU33697/01A priority patent/AU772949B2/en
Priority to PT01905671T priority patent/PT1248804E/pt
Priority to CA2396212A priority patent/CA2396212C/en
Priority to BR0107661-2A priority patent/BR0107661A/pt
Priority to IL15055101A priority patent/IL150551A0/xx
Priority to JP2001553825A priority patent/JP3978338B2/ja
Priority to IL150551A priority patent/IL150551A/en
Priority to NO20023266A priority patent/NO329816B1/no
Priority to ZA2002/05659A priority patent/ZA200205659B/en
Priority to US11/484,472 priority patent/US7491392B2/en
Priority to CY20061101860T priority patent/CY1107989T1/el
Priority to JP2007000148A priority patent/JP2007097598A/ja
Priority to US12/351,007 priority patent/US20090232803A1/en
Priority to US13/044,918 priority patent/US20110182894A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
GBGB0001448.0A 2000-01-21 2000-01-21 Organic compounds Ceased GB0001448D0 (en)

Priority Applications (38)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
MYPI20010226A MY155269A (en) 2000-01-21 2001-01-18 ANTIBODIES TO HUMAN IL-1ß
CO01003434A CO5261584A1 (es) 2000-01-21 2001-01-18 Anticuerpos para il-1 humana
IL15055101A IL150551A0 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
JP2001553825A JP3978338B2 (ja) 2000-01-21 2001-01-19 ヒトＩＬ−１βに対する抗体
HU0204156A HUP0204156A3 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
SK1035-2002A SK288054B6 (sk) 2000-01-21 2001-01-19 Antibody to IL-1 beta, IL-1 beta binding molecule, its use and process for production, first DNA construct, expression vector and pharmaceutical composition
CZ20022531A CZ302738B6 (cs) 2000-01-21 2001-01-19 Protilátka proti IL-1beta tvorená molekulou vázající IL-1beta, tato molekula pro použití jako lécivo, použití této molekuly pro výrobu léciva, odpovídající DNA konstrukty a expresní vektor, zpusob prípravy uvedené molekuly a farmaceutická kompozice o
ARP010100247A AR027253A1 (es) 2000-01-21 2001-01-19 Anticuerpos para il-1beta humana
SI200130698T SI1248804T2 (sl) 2000-01-21 2001-01-19 Rekombinantna protitelesa usmerjena proti humanemu interlevkinu-1 beta
AT01905671T ATE346868T1 (de) 2000-01-21 2001-01-19 Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
US10/181,324 US20030124617A1 (en) 2000-01-21 2001-01-19 Antibodies to human il 1-beta
MXPA02007091A MXPA02007091A (es) 2000-01-21 2001-01-19 Anticuerpos para il-1b humana.
ES01905671T ES2274865T5 (es) 2000-01-21 2001-01-19 Anticuerpos recombinantes para la interleuquina-1 beta humana.
PL356297A PL207642B1 (pl) 2000-01-21 2001-01-19 Przeciwciało wiążące IL-1ß, konstrukt DNA, wektor ekspresyjny, kompozycja farmaceutyczna, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
HK03102022.5A HK1050013A1 (zh) 2000-01-21 2001-01-19 抗人IL-1β抗體
KR1020027009374A KR100697126B1 (ko) 2000-01-21 2001-01-19 인간 ＩＬ-1β에 대한 항체
TR2002/01780T TR200201780T2 (tr) 2000-01-21 2001-01-19 İnsanlara özgü interlökin-1 beta' ya karşı rekombinant antikorlar
DE60124863T DE60124863T3 (de) 2000-01-21 2001-01-19 Gegen menschliche interleukin-1-beta gerichtete rekombinante antikörper
RU2002121649/13A RU2264413C2 (ru) 2000-01-21 2001-01-19 РЕКОМБИНАНТНОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ ИНТЕРЛЕЙКИНУ 1β
NZ519936A NZ519936A (en) 2000-01-21 2001-01-19 Antibodies to human Interleukin-1
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta
DK01905671.2T DK1248804T4 (da) 2000-01-21 2001-01-19 Rekombinante antistoffer mod humant interleukin-1-beta
PE2001000065A PE20011219A1 (es) 2000-01-21 2001-01-19 ANTICUERPOS PARA IL-1ß HUMANA
CN018039529A CN1395581B (zh) 2000-01-21 2001-01-19 重组人白细胞介素-1β抗体
EP01905671A EP1248804B2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
AU33697/01A AU772949B2 (en) 2000-01-21 2001-01-19 Antibodies to human IL-1beta
PT01905671T PT1248804E (pt) 2000-01-21 2001-01-19 Anticorpos contra il-1b humana
CA2396212A CA2396212C (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta
BR0107661-2A BR0107661A (pt) 2000-01-21 2001-01-19 Anticorpos para il-1/ß humana
IL150551A IL150551A (en) 2000-01-21 2002-07-02 Recombinant antibody against interleukin - 1 human beta, pharmaceutical compounds that include it, a construct of DNA that encodes it, a process for its preparation and uses in drug preparation
NO20023266A NO329816B1 (no) 2000-01-21 2002-07-05 Antistoffer mot humant IL-10, anvendelse av disse, DNA konstruksjoner, ekspresjonsvektor, fremgangsmate for fremstilling og farmasoytisk sammensetning
ZA2002/05659A ZA200205659B (en) 2000-01-21 2002-07-16 Recombinant antibodies to human interleukin-1 beta
US11/484,472 US7491392B2 (en) 2000-01-21 2006-07-11 Antibodies to human IL-1β
CY20061101860T CY1107989T1 (el) 2000-01-21 2006-12-29 Ανασυνδυασμενα αντισωματα της ανθρωπινης ιντepλευκινης-1 βητα
JP2007000148A JP2007097598A (ja) 2000-01-21 2007-01-04 ヒトＩＬ−１βに対する抗体
US12/351,007 US20090232803A1 (en) 2000-01-21 2009-01-09 Antibodies to human il-1beta
US13/044,918 US20110182894A1 (en) 2000-01-21 2011-03-10 Methods of treating diabetes using IL-1beta antibodies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds

Publications (1)

Publication Number Publication Date
GB0001448D0 true GB0001448D0 (en) 2000-03-08

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0001448.0A Ceased GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds

Country Status (33)

Country Link
US (4) US20030124617A1 (enExample)
EP (1) EP1248804B2 (enExample)
JP (2) JP3978338B2 (enExample)
KR (1) KR100697126B1 (enExample)
CN (1) CN1395581B (enExample)
AR (1) AR027253A1 (enExample)
AT (1) ATE346868T1 (enExample)
AU (1) AU772949B2 (enExample)
BR (1) BR0107661A (enExample)
CA (1) CA2396212C (enExample)
CO (1) CO5261584A1 (enExample)
CY (1) CY1107989T1 (enExample)
CZ (1) CZ302738B6 (enExample)
DE (1) DE60124863T3 (enExample)
DK (1) DK1248804T4 (enExample)
ES (1) ES2274865T5 (enExample)
GB (1) GB0001448D0 (enExample)
HK (1) HK1050013A1 (enExample)
HU (1) HUP0204156A3 (enExample)
IL (2) IL150551A0 (enExample)
MX (1) MXPA02007091A (enExample)
MY (1) MY155269A (enExample)
NO (1) NO329816B1 (enExample)
NZ (1) NZ519936A (enExample)
PE (1) PE20011219A1 (enExample)
PL (1) PL207642B1 (enExample)
PT (1) PT1248804E (enExample)
RU (1) RU2264413C2 (enExample)
SI (1) SI1248804T2 (enExample)
SK (1) SK288054B6 (enExample)
TR (1) TR200201780T2 (enExample)
WO (1) WO2001053353A2 (enExample)
ZA (1) ZA200205659B (enExample)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
MXPA02012867A (es) 2000-06-29 2003-09-05 Abbott Lab Anticuerpos de especificidad doble y metodos para la elaboracion y el uso de los mismos.
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20060094056A1 (en) * 2003-09-15 2006-05-04 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose treat, and evaluate inflammatory and autoimmune diseases
EP2857418B1 (en) 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PA8672101A1 (es) * 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
ES2569917T3 (es) * 2005-06-21 2016-05-13 Xoma (Us) Llc Anticuerpos y fragmentos de los mismos que se unen a IL-1beta
EP2848258B1 (en) * 2005-10-26 2017-12-13 Novartis AG Treatment of familial Mediterranean Fever with anti IL-1beta antibodies
RS55963B1 (sr) * 2005-12-29 2017-09-29 Janssen Biotech Inc Humana anti-il-23 antitela, kompozicije, metode i upotrebe
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
AU2007238677B2 (en) * 2006-04-14 2011-03-10 Novartis Ag Use of IL-I antibodies for treating ophthalmic disorders
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
EP3124045A3 (en) 2006-12-20 2017-05-03 Xoma (Us) Llc Treatment of il-1 beta related diseases
EP2114443A4 (en) * 2006-12-29 2011-08-10 Abbott Lab IL-1A / IL-1B ANTIBODY WITH DOUBLE SPECIFICITY
CA2679400A1 (en) 2007-02-28 2008-09-04 Schering Corporation Combination therapy for treatment of immune disorders
EP3406263A1 (en) * 2007-05-29 2018-11-28 Novartis AG New indications for anti-il-1beta therapy
DK2391650T3 (en) * 2007-12-20 2015-01-12 Xoma Us Llc Methods of treating gout
CA2727171A1 (en) * 2008-06-06 2009-12-10 Xoma Technology Ltd. Methods for the treatment of rheumatoid arthritis
CA2735939A1 (en) 2008-09-05 2010-03-11 Xoma Technology Ltd. Methods for improvement of beta cell function
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
WO2011140522A1 (en) * 2010-05-07 2011-11-10 Xoma Technology Ltd. METHODS FOR THE TREATMENT OF IL-1β RELATED CONDITIONS
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
KR102306967B1 (ko) 2010-08-02 2021-10-01 리제너론 파아마슈티컬스, 인크. Ｖｌ 도메인을 포함하는 결합 단백질을 생성하는 마우스
EP2614085B1 (en) 2010-09-10 2016-04-20 Apexigen, Inc. Anti-il-1 beta antibodies and methods of use
LT2738259T (lt) 2011-02-25 2020-03-10 Regeneron Pharmaceuticals, Inc. Adam6 pelės
PT3865581T (pt) 2011-08-05 2024-10-04 Regeneron Pharma Murganhos da cadeia leve universal humanizada
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
JP6320300B2 (ja) 2011-12-19 2018-05-09 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 座瘡を治療するための方法
PT3527070T (pt) 2011-12-20 2025-12-19 Regeneron Pharma Murganhos de cadeia leve humanizada
PT2814843T (pt) 2012-02-13 2020-06-18 Agency Science Tech & Res Anticorpos monoclonais humanos neutralizantes de il-b
EP3912464A1 (en) 2012-06-12 2021-11-24 Regeneron Pharmaceuticals, Inc. Humanized non-human animals with restricted immunoglobulin heavy chain loci
CN106255410B (zh) 2014-03-21 2020-01-10 瑞泽恩制药公司 产生单结构域结合蛋白的非人动物
CN106164092A (zh) 2014-03-21 2016-11-23 瑞泽恩制药公司 表现不同结合特征的vl抗原结合蛋白
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
ES3064335T3 (en) 2018-03-05 2026-04-24 Janssen Biotech Inc Methods of treating crohn's disease with anti-il23 specific antibody
CN110818793A (zh) 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
MX2021005905A (es) 2018-11-20 2021-06-23 Janssen Biotech Inc Metodo seguro y eficaz para tratar la psoriasis con el anticuerpo especifico anti-il-23.
US11780911B2 (en) 2019-05-23 2023-10-10 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
MX2022014430A (es) 2020-05-21 2023-02-22 Janssen Biotech Inc Método para tratar la enfermedad inflamatoria del intestino con una terapia de combinación de anticuerpos para il-23 y tnf alfa.
CN116063489B (zh) * 2022-10-21 2026-01-30 杭州靶向食品科技有限公司 一种治疗痛风的单克隆抗体及其相应的组合物
CN121511262A (zh) 2023-06-28 2026-02-10 北京哲源科技有限责任公司 靶向pd-l1和il-1的双特异性抗体及其用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1248804B1 (en) 2006-11-29
US20030124617A1 (en) 2003-07-03
WO2001053353A2 (en) 2001-07-26
MXPA02007091A (es) 2002-12-13
AR027253A1 (es) 2003-03-19
KR20020073178A (ko) 2002-09-19
EP1248804A2 (en) 2002-10-16
ATE346868T1 (de) 2006-12-15
RU2002121649A (ru) 2004-03-10
NO329816B1 (no) 2010-12-27
NZ519936A (en) 2004-02-27
IL150551A0 (en) 2003-02-12
NO20023266D0 (no) 2002-07-05
CA2396212C (en) 2013-04-02
EP1248804B2 (en) 2009-12-02
HUP0204156A2 (hu) 2003-03-28
BR0107661A (pt) 2002-11-19
US7491392B2 (en) 2009-02-17
JP2007097598A (ja) 2007-04-19
DE60124863T2 (de) 2007-04-26
PL356297A1 (en) 2004-06-28
CZ20022531A3 (cs) 2002-10-16
US20090232803A1 (en) 2009-09-17
DK1248804T3 (da) 2007-02-26
AU772949B2 (en) 2004-05-13
CA2396212A1 (en) 2001-07-26
SK288054B6 (sk) 2013-03-01
IL150551A (en) 2010-11-30
ES2274865T5 (es) 2010-04-19
SI1248804T2 (sl) 2010-04-30
DK1248804T4 (da) 2010-04-06
SK10352002A3 (sk) 2003-03-04
PT1248804E (pt) 2007-02-28
KR100697126B1 (ko) 2007-03-20
CY1107989T1 (el) 2013-09-04
SI1248804T1 (sl) 2007-06-30
US20060251660A1 (en) 2006-11-09
MY155269A (en) 2015-09-30
HUP0204156A3 (en) 2005-09-28
RU2264413C2 (ru) 2005-11-20
TR200201780T2 (tr) 2003-01-21
JP3978338B2 (ja) 2007-09-19
US20110182894A1 (en) 2011-07-28
ZA200205659B (en) 2003-12-31
JP2003520595A (ja) 2003-07-08
CO5261584A1 (es) 2003-03-31
AU3369701A (en) 2001-07-31
DE60124863T3 (de) 2010-05-20
PL207642B1 (pl) 2011-01-31
NO20023266L (no) 2002-08-28
PE20011219A1 (es) 2001-12-17
WO2001053353A3 (en) 2002-04-04
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
HK1050013A1 (zh) 2003-06-06
ES2274865T3 (es) 2007-06-01
CN1395581B (zh) 2010-10-13
CN1395581A (zh) 2003-02-05

Similar Documents

Publication Publication Date Title
AU8389101A (en) Organic compounds
GB0010955D0 (en) Organic compounds
GB0006398D0 (en) Organic compounds
GB0003111D0 (en) Organic compounds
GB0008694D0 (en) Organic compounds
GB0008785D0 (en) Organic compounds
GB0002100D0 (en) Organic compounds
AU3458802A (en) Organic compounds
GB0007108D0 (en) Organic compounds
GB0007911D0 (en) Organic compounds
GB0002740D0 (en) Organic compounds
GB0009037D0 (en) Organic compounds
GB0009054D0 (en) Organic compounds
GB0009053D0 (en) Organic compounds
GB0009055D0 (en) Organic compounds
GB0010200D0 (en) Organic compounds
GB0001929D0 (en) Organic compounds
GB0002101D0 (en) Organic compounds
GB0010205D0 (en) Organic compounds
GB0010210D0 (en) Organic compounds
GB0001697D0 (en) Organic compounds
GB0009031D0 (en) Organic compounds
GB0010208D0 (en) Organic compounds
GB0010956D0 (en) Organic compounds
GB0006735D0 (en) Organic compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)